[go: up one dir, main page]

CN101677943B - 使用苯甲醇的多剂量浓缩艾司洛尔 - Google Patents

使用苯甲醇的多剂量浓缩艾司洛尔 Download PDF

Info

Publication number
CN101677943B
CN101677943B CN2008800170791A CN200880017079A CN101677943B CN 101677943 B CN101677943 B CN 101677943B CN 2008800170791 A CN2008800170791 A CN 2008800170791A CN 200880017079 A CN200880017079 A CN 200880017079A CN 101677943 B CN101677943 B CN 101677943B
Authority
CN
China
Prior art keywords
compositions
esmolol
benzyl alcohol
buffer agent
concentrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800170791A
Other languages
English (en)
Other versions
CN101677943A (zh
Inventor
迪帕克·蒂瓦里
乔治·奥沃
列哈·纳亚克
肯尼斯·E·布尔霍普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of CN101677943A publication Critical patent/CN101677943A/zh
Application granted granted Critical
Publication of CN101677943B publication Critical patent/CN101677943B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明公开了基本上不含其它有关的艾司洛尔酯的浓缩的艾司洛尔注射剂和稀释的艾司洛尔组合物。浓缩艾司洛尔制剂包含约25-1000mg/ml的艾司洛尔和约1-25％w/v的苯甲醇及其组合。组合物还可用作多剂量组合物。本发明还公开了通过稀释本发明的浓缩品而制备的稀释的即用艾司洛尔组合物。本发明还公开了制备和使用本发明即用组合物的方法。

Description

使用苯甲醇的多剂量浓缩艾司洛尔
发明背景
本发明涉及稳定性增强的浓缩艾司洛尔制剂。更具体地说，本发明涉及用苯甲醇稳定的浓缩艾司洛尔制剂。本发明的组合物还适合作为多剂量组合物。另外，本发明涉及通过稀释本发明的浓缩艾司洛尔组合物制备的即用(ready-to-use)稀释组合物。
艾司洛尔(及其药学可接受的盐，例如盐酸盐)和有关化合物具有β-肾上腺素能阻断活性。β-阻断剂当以适当剂量给药时，是用于治疗和预防心脏病的治疗有效药剂。艾司洛尔是短效β-阻断剂，通常在紧急救护背景下被使用，以控制患者的心率。艾司洛尔的短效性质是由于它的不稳定的脂族甲酯基在血液中快速水解所致。
艾司洛尔的即用等渗浓缩制剂公开在美国专利Nos.5,017,609、6,310,094和6,528,540中，所述文献作为参考并入本文。制备艾司洛尔的方法和使用这样的化合物治疗或预防心脏病的方法公开在美国专利4,387,103和4,593,119中，所述文献作为参考并入本文。目前市售的艾司洛尔浓缩制剂受美国专利5,017,609的保护，其包含约250mg/ml的艾司洛尔盐酸盐、25体积％的乙醇、25体积％的丙二醇、17mg/ml的三水乙酸钠和0.715体积％的冰醋酸。该组合物不计划用于直接注射，而是用适当的稀释剂进行后续稀释。
艾司洛尔盐酸盐{3-[4-[2-羟基-3-(异丙基氨基)丙氧基]苯基]丙酸甲酯盐酸盐}在水中的稳定性由不稳定的脂族甲酯基团的酸/碱催化水解速率来介导，并且其降解成为ASL-8123{甲基-3-[4-[2-羟基-3-(异丙基氨基)丙氧基]苯基]丙酸}。即用等渗制剂在真正的含水制剂中解决了一些稳定性问题并且只具有一种降解物ASL-8123。目前市售的浓缩制剂采用赋形剂(乙醇和丙二醇)来稳定水解反应，但是这些赋形剂导致形成其它有关的酯降解物。因此，目前市售的艾司洛尔浓缩制剂在长期储存条件下导致除了ASL-8123之外还形成艾司洛尔的乙酯和丙酯。另外，用来稳定目前市售的艾司洛尔浓缩制剂的赋形剂(乙醇和丙二醇)已经与潜在的注射部位疼痛或刺激有关。
因此，希望提供稳定的浓缩艾司洛尔组合物，其消除了有关酯降解物的形成，不包含可能具有刺激性的丙二醇和乙醇赋形剂，比现有技术的浓缩组合物的制造更简单，并且任选可被保存使得能够用于多剂量应用。
发明概述
在本发明的一个方面，提供了浓缩艾司洛尔制剂。浓缩艾司洛尔制剂包含约25-1000mg/ml的艾司洛尔(或其药学可接受的盐)、约1到25体积％的苯甲醇和任选的约0.005到约2摩尔(M)的缓冲剂。该组合物的pH调节为约3.5到约7.0之间。苯甲醇，一般被用作防腐剂，已经出人意料地被发现可稳定本发明的浓缩艾司洛尔组合物。
在本发明的另一个方面，提供了即用组合物和该组合物的给药方法。该方法包括以下步骤：提供约25-1000mg/ml的艾司洛尔(或其药学可接受的盐)和1-25％重量/体积的苯甲醇的浓缩艾司洛尔制剂，从该液体选择一定体积用适当的稀释剂进一步稀释，然后将稀释的产品给患者注射。
本发明的优点是，与现有技术的浓缩艾司洛尔组合物不同，本发明的制剂不形成其它有关的艾司洛尔酯的降解物。
本发明的另一个优点是其提供了制剂的多剂量应用的灵活性，而没有微生物交叉污染。
本发明的另一个优点是其减少了由丙二醇和乙醇赋形剂引起的注射部位疼痛/刺激的可能性。
本发明的另一个优点是其提供了无菌的浓缩艾司洛尔组合物，其包含较少的赋形剂并且比现有技术的浓缩品的制备更简单。
附图说明
图1是描述艾司洛尔在乙醇和丙二醇存在下发生酯交换产生相应 的酯的化学路线。
发明详述
本发明的组合物包含艾司洛尔或其药学可接受的盐例如盐酸盐，和苯甲醇。本文使用的“艾司洛尔”是指艾司洛尔游离碱及其药学可接受的盐。浓缩品中艾司洛尔的浓度约25-1000mg/ml，优选约250mg/ml。
如上所述，艾司洛尔的主要降解途径是其脂族羧甲酯部分水解产生ASL-8123。这一降解取决于pH、缓冲剂浓度和艾司洛尔浓度。目前市售的艾司洛尔浓缩制剂由于乙醇和丙二醇的存在得以稳定。然而，过去的稳定性数据表明艾司洛尔在这些溶剂存在下经历酯交换反应，产生艾司洛尔的乙酯和丙二醇酯(参见图1)。
本发明的组合物包含一定量的苯甲醇以稳定艾司洛尔浓缩组合物。尽管苯甲醇一般被用作防腐剂，但是出乎意料地发现其稳定本发明的浓缩艾司洛尔组合物。通常，苯甲醇的存在量取决于存在的艾司洛尔浓度。苯甲醇在组合物中的典型范围为约1到25％重量/体积(w/v)。对于250mg/ml的艾司洛尔浓度而言，苯甲醇优选以约10％w/v的浓度存在。
本发明的浓缩品还可包含药学可接受的缓冲剂以帮助保持pH在约3.5到约7.0的范围。pH优选保持在约4.5到约5.5之间，更优选保持在4.9到5.1之间。当pH在4.0到6.0范围以外时，艾司洛尔的降解发生最快，并且在约5.0的pH周围最稳定。适当的缓冲剂是在所需pH范围提供充分缓冲能力并且对注射给患者是药学可接受的那些缓冲剂。可用于本发明的缓冲剂的实例包括但不限于乙酸盐、谷氨酸盐、柠檬酸盐、酒石酸盐、苯甲酸盐、乳酸盐、葡糖酸盐、磷酸盐和甘氨酸及其共轭酸。缓冲剂的浓度为约0.005到约2M。在优选的实施方案中，缓冲剂包含乙酸钠和冰醋酸的组合。缓冲剂的优选组合包括约0.005到约0.3M的乙酸钠和约0.05到约0.3M的冰醋酸。
用于容纳艾司洛尔浓缩品的适当容器是本领域已知的。它们包括小瓶、注射器和安瓿形式。容器可由聚合物材料或玻璃制成。优选的聚合物容器不含聚氯乙烯(PVC)。容器优选具有优异的屏障性质。优选的容器保留有水分屏障，诸如包括屏障层或二级包装的玻璃容器或聚合物容器。铝套袋是优选的水分屏障，用作自身缺乏水分屏障的聚合物容器的二级包装。优选的容器应能经得起最终灭菌，诸如压热。
本发明的组合物是无菌的。该组合物优选被制备然后在其最终容器中通过压热进行灭菌。或者，浓缩品可被无菌制备或单独通过压热最终灭菌，然后使用无菌程序置于无菌容器中。在制药工业中被用来实现成品最终灭菌的典型压热周期是121℃历时15分钟。本发明的艾司洛尔浓缩品可以在115到130℃压热约5到40分钟的时段，稳定性合格。压热灭优选在约119到122℃的温度范围内进行约10到36分钟的时间段。
在一个实施方案中，将浓缩品置于透明玻璃或塑料注射器中并进行最终灭菌。这些预灌装注射器可以提供成各种体积，从而允许通过将预灌装注射器的内容物分配到标准或定制的预灌装静脉流体袋中，而快速和容易地制备小体积或大体积的非肠道剂量。
在另一个实施方案中，本发明的浓缩艾司洛尔组合物被包装在密封小瓶中，优选I型处理玻璃的小瓶。
本发明还涉及使用本发明的艾司洛尔浓缩品制备的稀释的艾司洛尔组合物。执业医师可以使用用于给患者输注的优选稀释剂制得稀释浓度的艾司洛尔。适当的稀释剂包括本领域有技术的执业医师使用的稀释剂。典型实例包括但不限于氯化钠溶液，林格液或葡萄糖溶液。当需要时，艾司洛尔的稀释浓度根据需要而变，典型的浓度范围为约5至约25mg/ml的艾司洛尔，优选10mg/ml。
本发明稀释组合物的适当给药途径包括静脉内、皮下、皮内、肌肉内、关节内和鞘内。稀释组合物优选通过静脉内输注给药。
以下实施例的组合物和制备方法进一步说明了本发明，但不应解释成限制其范围。
实施例1
以下描述了包含250mg/ml的艾司洛尔盐酸盐和苯甲醇的艾司洛尔浓缩品的制备。该组合物各成分的浓度如下所示：
  成分   浓度
  艾司洛尔   250mg/mL
  三水乙酸钠   17mg/mL
  冰醋酸   0.00715mL/mL
  苯甲醇，USP   10％w/v
  注射用水，USP   适量
用于混合、过滤和灌装的设备和玻璃器皿经过彻底洗涤和除热原。将过滤器组件、灌装管组件和其它部件和设备进行灭菌。将冷注射用水的最终容积的百分之八十(80％)集中在混合槽中。然后将冰醋酸和乙酸钠加入到该槽中。将艾司洛尔盐酸盐称重并加入到该槽中。称重需要量的苯甲醇并加入到该槽中。将溶液搅拌直到所有的赋形剂溶解为止。然后使用氢氧化钠或盐酸将溶液调节到pH 5.0。将溶液用注射用水补足到最终体积并混合。将溶液灌装在10毫升I型处理的燧石安瓿中并密封。将产品在122℃灭菌20分钟。
实施例2
艾司洛尔盐酸盐在55℃下在水中或水-苯甲醇溶液中的稳定性分别被概括在表1和表2中。实施例1的制剂在55℃的水中的稳定性概括在表3中。如数据所显示的，苯甲醇的存在大大降低了艾司洛尔的降解(表2)。并且当苯甲醇与保持pH在5.0的缓冲剂一起使用时，艾司洛尔的降解被进一步降低(表3)。丙酯降解物峰(根据HPLC图谱，在0.55和0.60的近似相对滞留时间处)和乙酯降解物峰(在2.10的近似相对滞留时间处)的缺乏，表明本发明不包含在现有技术的目前市售的艾司洛尔浓缩制剂中所发现的任何降解物。用苯甲醇代替乙醇和丙二醇消除了艾司洛尔的酯交换反应以及乙酯和丙二醇酯降解物的形成，从而改善了现有技术浓缩制剂的稳定性和安全性模式。
表1.250mg/ml艾司洛尔盐酸盐在55℃的水中的稳定性
Figure G2008800170791D00061
*在RRT＝0.55，0.60和2.10处
表2.带有10％苯甲醇的250mg/ml艾司洛尔盐酸盐在55℃水中的稳定性
Figure G2008800170791D00071
*在RRT＝0.55，0.60和2.10处
表3.带有10％苯甲醇的250mg/ml艾司洛尔盐酸盐在55℃的经缓冲的水中的稳定性
Figure G2008800170791D00072
*在RRT＝0.55，0.60和2.10处
尽管已经参考某些优选的实施方案对本发明进行了描述，但应理解的是优选的实施方案仅仅说明本发明的原理。因此，本领域技术人员可进行改变和/或变化而不脱离所附权利要求所限定的本发明的真实精神和范围。

Claims (17)

1.浓缩的艾司洛尔组合物，其包含：
a)25-1000mg/ml的艾司洛尔；和
b)1-25%w/v的苯甲醇；
其中组合物的pH为3到7。
2.权利要求1的组合物，还包含缓冲剂。
3.权利要求2的组合物，其中缓冲剂包括乙酸盐、谷氨酸盐、柠檬酸盐、酒石酸盐、苯甲酸盐、乳酸盐、葡糖酸盐、磷酸盐和甘氨酸中的至少一种及其共轭酸。
4.权利要求3的组合物，其中缓冲剂包含乙酸钠和乙酸。
5.权利要求2的组合物，其中缓冲剂的存在量为0.005到2M。
6.权利要求1的组合物，其包含：
a)250mg/ml的艾司洛尔；
b)10%w/v的苯甲醇；和
c)0.1M的乙酸盐。
7.权利要求1的组合物，其包含：
a)50mg/ml的艾司洛尔；
b)2%w/v的苯甲醇；
c)0.1M的乙酸盐。
8.包含艾司洛尔的即用组合物，其通过以下方法制备：
a)提供一定体积的第一组合物，所述第一组合物包含25-1000mg/ml的艾司洛尔和1-25%w/v的苯甲醇，其中第一组合物的pH为3到7；和
b)将一定体积的第一组合物用一定体积的第二组合物稀释，所述第二组合物包含用于非肠道给药的药学可接受的稀释剂。
9.权利要求8的组合物，其中第一组合物还包含缓冲剂。
10.权利要求9的组合物，其中缓冲剂包括乙酸盐、谷氨酸盐、柠檬酸盐、酒石酸盐、苯甲酸盐、乳酸盐、葡糖酸盐、磷酸盐和甘氨酸中的至少一种及其共轭酸。
11.权利要求10的组合物，其中缓冲剂包含乙酸钠和乙酸。
12.权利要求9的组合物，其中缓冲剂的存在量为0.005到2M。
13.权利要求8的组合物，其中第二组合物选自：磷酸盐缓冲盐水和林格液。
14.权利要求9的组合物，其中第一组合物包含：
a)250mg/ml的艾司洛尔；
b)10%w/的苯甲醇；和
c)0.1M的乙酸盐。
15.权利要求9的组合物，其中第一组合物包含0.1M的乙酸盐；
a)50mg/ml的艾司洛尔；和
b)2%w/v的苯甲醇。
16.浓缩的艾司洛尔组合物，其组成如下：
a)25-1000mg/ml的艾司洛尔；
b)1-25%w/v的苯甲醇；
c)0.005-2M的缓冲剂，
其中组合物的pH为3到7。
17.权利要求8的组合物，其中第二组合物选自：盐水和葡萄糖溶液。
CN2008800170791A 2007-05-22 2008-05-15 使用苯甲醇的多剂量浓缩艾司洛尔 Expired - Fee Related CN101677943B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/752,103 US8722736B2 (en) 2007-05-22 2007-05-22 Multi-dose concentrate esmolol with benzyl alcohol
US11/752,103 2007-05-22
PCT/US2008/063755 WO2008147715A2 (en) 2007-05-22 2008-05-15 Multi-dose concentrate esmolol with benzyl alcohol

Publications (2)

Publication Number Publication Date
CN101677943A CN101677943A (zh) 2010-03-24
CN101677943B true CN101677943B (zh) 2013-10-23

Family

ID=40072995

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800170791A Expired - Fee Related CN101677943B (zh) 2007-05-22 2008-05-15 使用苯甲醇的多剂量浓缩艾司洛尔

Country Status (10)

Country Link
US (1) US8722736B2 (zh)
EP (1) EP2164464A2 (zh)
JP (1) JP2010528025A (zh)
KR (1) KR20100022992A (zh)
CN (1) CN101677943B (zh)
AU (1) AU2008256949B2 (zh)
BR (1) BRPI0811850A2 (zh)
CA (1) CA2686566A1 (zh)
MX (1) MX2009012614A (zh)
WO (1) WO2008147715A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009079679A2 (de) 2007-12-21 2009-07-02 Aop Orphan Pharmaceuticals Ag Pharmazeutische zusammensetzung
ES2443159T3 (es) 2009-09-22 2014-02-18 Vlife Sciences Technologies Pvt Ltd. Formulación tópica para úlceras del pie diabético

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1455669A (zh) * 2001-01-12 2003-11-12 巴克斯特国际公司 艾司洛尔制剂
CN1753661A (zh) * 2003-02-24 2006-03-29 美国诺华卡迪亚公司 用于治疗心脏及肾脏疾病的腺苷a1受体拮抗剂

Family Cites Families (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2525071A (en) 1945-11-30 1950-10-10 Standard Oil Dev Co Laminated sheet material and compositions
BE515475A (zh) 1951-11-13
US2745785A (en) 1952-10-29 1956-05-15 American Home Prod Therapeutic composition comprising tabular nu, nu'-dibenzylethylenediamine di-penicillin, and process for preparing same
US3685261A (en) 1971-02-16 1972-08-22 Environeering Wet scrubber for contaminated gas
GB1472793A (en) 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4798846A (en) 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
JPS597693B2 (ja) 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4593119A (en) 1980-11-28 1986-06-03 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
US4387103A (en) 1980-11-28 1983-06-07 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4608278A (en) 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
EP0179808B1 (en) 1984-04-09 1991-10-30 The Du Pont Merck Pharmaceutical Company Pharmaceutical composition suitable for treatment or prophylaxis of cardiac disorders
CA1282405C (en) 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
US5354563A (en) 1985-07-15 1994-10-11 Research Development Corp. Of Japan Water dispersion containing ultrafine particles of organic compounds
US5023271A (en) 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US5171566A (en) 1986-05-16 1992-12-15 The Green Cross Corporation Flurbiprofen derivative ophthalmic preparation
GB8618846D0 (en) 1986-08-01 1986-09-10 Smithkline Beckman Corp Chemical process
CA1338736C (fr) 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2608942B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US5174930A (en) 1986-12-31 1992-12-29 Centre National De La Recherche Scientifique (Cnrs) Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of oligolamellar liposomes of submicron dimensions
FR2634397B2 (fr) 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
IL86211A (en) 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
GB8901254D0 (en) 1989-01-20 1989-03-15 Allied Colloids Ltd Particulate materials and their production
FR2631826B1 (fr) 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
US4857552A (en) * 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
IL90561A (en) 1988-06-08 1993-08-18 Fountain Pharm Inc Method for making solvent dilution microcarriers
US5269979A (en) 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
DE68904483T2 (de) 1988-06-30 1993-05-19 Centre Nat Rech Scient Verfahren zur herstellung von kolloidalen dispergierbaren proteinsystemen, wie nanopartikeln.
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US5474989A (en) 1988-11-11 1995-12-12 Kurita Water Industries, Ltd. Drug composition
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
CH677886A5 (zh) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
FR2651680B1 (fr) 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
JP2602964B2 (ja) 1989-10-16 1997-04-23 裕 水島 プロスタグランジン類縁体およびその脂肪乳剤
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5078994A (en) 1990-04-12 1992-01-07 Eastman Kodak Company Microgel drug delivery system
US5091187A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
JP3282731B2 (ja) 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5306519A (en) 1991-05-23 1994-04-26 Universal Foods Corporation Syrup for confections and methods for using same
IT1247472B (it) 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5250236A (en) 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
CA2078388A1 (en) 1991-10-02 1993-04-03 Mridula Nair Biocompatible emulsion particles
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5298483A (en) 1992-03-30 1994-03-29 Tropicana Products, Inc. New matter of composition and method for using the same as plant bioregulators
US5389263A (en) 1992-05-20 1995-02-14 Phasex Corporation Gas anti-solvent recrystallization and application for the separation and subsequent processing of RDX and HMX
DK0644755T3 (da) 1992-06-10 1997-09-22 Nanosystems Llc Overflademodificerede NSAID-nanopartikler
JP3961029B2 (ja) 1992-06-24 2007-08-15 博 木戸 インフルエンザウィルス感染防止剤
SE9202128D0 (sv) 1992-07-09 1992-07-09 Astra Ab Precipitation of one or more active compounds in situ
US5417956A (en) 1992-08-18 1995-05-23 Worcester Polytechnic Institute Preparation of nanophase solid state materials
US5466646A (en) 1992-08-18 1995-11-14 Worcester Polytechnic Institute Process for the preparation of solid state materials and said materials
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
DE4305003A1 (de) 1993-02-18 1994-08-25 Knoll Ag Verfahren zur Herstellung kolloidaler wäßriger Lösungen schwer löslicher Wirkstoffe
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5885486A (en) 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
FR2703927B1 (fr) 1993-04-13 1995-07-13 Coletica Utilisation d'une réaction de transacylation entre un polysaccharide estérifié et une polyamine pour former en milieu aqueux une membrane au moins en surface de particules gélifiées.
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
ATE211135T1 (de) 1993-09-24 2002-01-15 Univ British Columbia Aminocyclohexylester und ihre anwendung
SE9303574D0 (sv) 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method the manufacturing thereof
DE69411583T2 (de) 1993-11-15 1999-02-18 Zeneca Ltd., London Mikrokapseln, die suspensionen von biologisch aktiven verbindungen enthalten
US5468224A (en) 1993-11-30 1995-11-21 Souryal; Tarek O. Methods of color coding injectable medications
JP2699839B2 (ja) 1993-12-03 1998-01-19 日本電気株式会社 半導体装置の製造方法
IE940292A1 (en) 1994-04-06 1995-10-18 Elan Corp Plc Biodegradable microcapsules and method for their manufacture
JP2865554B2 (ja) 1994-04-08 1999-03-08 セントラル硝子株式会社 フルオロメチル−１，１，１，３，３，３−ヘキサフルオロイソプロピルエーテルのガスクロマトグラフ分析
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
FR2721510B1 (fr) 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticules filtrables dans des conditions stériles.
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
ATE187079T1 (de) 1994-09-27 1999-12-15 Nycomed Imaging As Kontrastmittel
US5720551A (en) 1994-10-28 1998-02-24 Shechter; Tal Forming emulsions
SE9403846D0 (sv) 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
AU4862796A (en) 1995-02-06 1996-08-27 Nanosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
JP4484247B2 (ja) 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
US5605785A (en) 1995-03-28 1997-02-25 Eastman Kodak Company Annealing processes for nanocrystallization of amorphous dispersions
ATE212545T1 (de) 1995-03-28 2002-02-15 Fidia Advanced Biopolymers Srl Nanosphären mit einem biokompatiblen polysaccharid
IE75744B1 (en) 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
FR2735978B1 (fr) 1995-06-30 1997-09-19 Sanofi Sa Composition pharmaceutique d'amiodarone pour administration parenterale
DK0752245T3 (da) 1995-07-05 2002-09-09 Europ Economic Community Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US5977172A (en) 1995-09-13 1999-11-02 Nippon Shinyaku Co., Ltd. PGE1 -containing-freeze dried preparation and process for the production thereof
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5637625A (en) 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
KR20000010696A (ko) 1996-05-02 2000-02-25 우에하라 아끼라 수 난용성 산성 약물의 현탁액제
MY118174A (en) 1996-05-07 2004-09-30 Alkermes Inc Process for the preparation of microparticles
BR9706897B1 (pt) 1996-05-20 2010-09-21 forma de dosagem farmacêutica.
NZ333844A (en) 1996-08-22 2000-10-27 Res Triangle Pharm Ltd Compositions comprising mircoparticles of water-insoluble substances and method for preparing same
US6344271B1 (en) 1998-11-06 2002-02-05 Nanoenergy Corporation Materials and products using nanostructured non-stoichiometric substances
DE19637517A1 (de) 1996-09-13 1998-03-19 Basf Ag Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen
WO1998014180A1 (en) 1996-10-03 1998-04-09 Dmitri Kirpotin Hydrophilic microparticles and methods to prepare same
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
WO1998027072A1 (en) 1996-12-17 1998-06-25 Cordant Technologies, Inc. Salting-out process of crystallizing 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5.5.0.0?5,903,11¿]-dodecane
US5874111A (en) 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
IT1292142B1 (it) 1997-06-12 1999-01-25 Maria Rosa Gasco Composizione farmaceutica in forma di microparticelle lipidiche solide atte alla somministrazione parenterale
KR19990001564A (ko) 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6221332B1 (en) 1997-08-05 2001-04-24 Microfluidics International Corp. Multiple stream high pressure mixer/reactor
DE19737481A1 (de) 1997-08-28 1999-03-04 Hoechst Ag Sphärische lineare Polysaccharide enthaltende Mikropartikel
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
US5886239A (en) 1997-11-21 1999-03-23 Baxter International Inc. Method of preparing monofluoromethyl ethers
US6083514A (en) 1998-01-09 2000-07-04 Abbott Laboratories Polymethylpentene container for an inhalation anesthetic
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
IL138765A0 (en) 1998-03-30 2001-10-31 Rtp Pharma Inc Compositions containing microparticles of water-insoluble substances and method for their preparation
AU3705799A (en) 1998-04-09 1999-11-01 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
FR2777193B1 (fr) 1998-04-14 2001-06-08 Coletica Particule a groupement hydroxamique chelatante d'ions metalliques et leur utilisation en cosmetique ou en pharmacie
WO1999059535A1 (en) 1998-05-15 1999-11-25 Unilever Plc Oral composition comprising capsules
US6696019B2 (en) 1998-06-15 2004-02-24 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
IL140276A0 (en) 1998-06-19 2002-02-10 Rtp Pharma Inc Processes to generate submicron particles of water-insoluble compounds
FR2780901B1 (fr) 1998-07-09 2000-09-29 Coletica Particules, en particulier micro- ou nanoparticules de monosaccharides et oligosaccharides reticules, leurs procedes de preparation et compositions cosmetiques, pharmaceutiques ou alimentaires en contenant
US6153225A (en) 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6238677B1 (en) 1998-08-18 2001-05-29 The United States Of America As Represented By The Secretary Of Agriculture Starch microcapsules for delivery of active agents
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
SE9804001D0 (sv) 1998-11-23 1998-11-23 Astra Ab New process
US6365191B1 (en) 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6100302A (en) 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
KR100331529B1 (ko) 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US7338657B2 (en) 2001-03-15 2008-03-04 Biosphere Medical, Inc. Injectable microspheres for tissue construction
JP5102423B2 (ja) 2000-04-20 2012-12-19 オバン・エナジー・リミテッド 改善された水不溶性薬剤粒子の処理
JP3412606B2 (ja) 2000-08-04 2003-06-03 株式会社島津製作所 レーザ回折・散乱式粒度分布測定装置
CA2419115C (en) 2000-08-15 2011-03-08 Board Of Trustees Of The University Of Illinois Microparticles, and method and apparatus for forming same
US6635223B2 (en) 2000-10-25 2003-10-21 Andreas Maerz Method for inactivating micro-organisms using high pressure processing
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
US7105176B2 (en) 2000-11-29 2006-09-12 Basf Aktiengesellschaft Production of solid preparations of water-soluble, sparingly water-soluble or water-insoluble active compounds
FR2817478A1 (fr) 2000-12-04 2002-06-07 Oreal Suspensions aqueuses de nanospheres de principes actifs lipophiles
DE10063712C1 (de) 2000-12-20 2002-08-29 Stiftung A Wegener Inst Polar Mikrobiologisches Verfahren zur Biosynthese der natürlichen blau-violetten Farbstoffe Violacein und Desoxyviolacein und deren Verwendung
US20030072807A1 (en) 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20030096013A1 (en) 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6310094B1 (en) 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
US20040022861A1 (en) 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
US20030054042A1 (en) 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0204772D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Pharmaceutical dosage forms
FR2838969B1 (fr) 2002-04-30 2006-05-19 Ellipse Pharmaceuticals Procede de sterilisation par haute pression de compositions pharmaceutiques sous forme micro ou nanodispersee et compositions ainsi obtenues
EP1417962A1 (de) 2002-11-06 2004-05-12 AOP Orphan Pharmaceuticals AG Verfahren zur Herstellung eines Arzneimittels enthaltend Esmolol
SE523535C2 (sv) 2002-12-20 2004-04-27 Tetra Laval Holdings & Finance Förfarande för värmebehandling av en förpackning.
US20040229901A1 (en) 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
EP1628641A2 (en) 2003-05-19 2006-03-01 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
US20060286037A1 (en) * 2003-08-08 2006-12-21 Ono Pharmaceutical Co., Ltd. Heart-slowing drug containing short-acting ß blocker as the active ingredient
WO2005079758A1 (en) 2004-02-13 2005-09-01 Bioavailability, Inc. A microemulsion preparation of high concentration propofol for anesthetic uses
EE05278B1 (et) 2004-03-23 2010-02-15 As Laser Diagnostic Instruments Meetod vedelike automaatseks krpteerimisega markeerimiseks ja j„rgnevaks identifitseerimiseks

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1455669A (zh) * 2001-01-12 2003-11-12 巴克斯特国际公司 艾司洛尔制剂
CN1753661A (zh) * 2003-02-24 2006-03-29 美国诺华卡迪亚公司 用于治疗心脏及肾脏疾病的腺苷a1受体拮抗剂

Also Published As

Publication number Publication date
US20080293810A1 (en) 2008-11-27
CA2686566A1 (en) 2008-12-04
WO2008147715A3 (en) 2009-05-22
WO2008147715A2 (en) 2008-12-04
BRPI0811850A2 (pt) 2014-11-18
AU2008256949A1 (en) 2008-12-04
JP2010528025A (ja) 2010-08-19
EP2164464A2 (en) 2010-03-24
US8722736B2 (en) 2014-05-13
AU2008256949B2 (en) 2013-02-07
MX2009012614A (es) 2009-12-11
KR20100022992A (ko) 2010-03-03
CN101677943A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
CN1981739B (zh) 艾司洛尔制剂
US9474732B2 (en) Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products
ES2272720T3 (es) Formulacion de esmolol.
CN101674803A (zh) 浓艾司洛尔
CN101677943B (zh) 使用苯甲醇的多剂量浓缩艾司洛尔
US8426467B2 (en) Colored esmolol concentrate
JP4074457B2 (ja) ヘパリン溶液入りプレフィルドシリンジ製剤およびその製造方法
US20060167072A1 (en) Liquid pharmaceutical formulations of palonosetron
US20230233453A1 (en) Suxamethonium composition and prefilled syringe thereof
MXPA00000973A (es) Composiciones inyectables de alatrofloxacina previamente mezcladas.
US20170035729A1 (en) Pharmaceutical composition for treating migraine
MXPA94003569A (en) Stable quinolone and naphthyridine premix formulations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131023

Termination date: 20140515